Skip to main content
S&P 5007,718.60-0.38%DOW53,414.25-0.51%NASDAQ26,506.99-0.29%BTC$79,261.00-1.08%ETH$2,492.30-0.82%GOLD$4,466.30-0.23%OIL$92.40+1.01%
Smart Investors Daily
Gilead Sciences, Inc. logo

NYSE · GILD

Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

$151.00

Down-$0.23 (-0.15%)

Updated Sep 8, 2026, 7:53 AM

SID Score

7.6/10

Composite research score

Smart Money

44/100

Neutral

Market cap
152.89B
P/E ratio
18.89
Dividend yield
2.60%
52-week range
$116.88 – $157.29
Volume
6.18M
Avg. volume
7.34M

Price performance

GILD price history

1M range · 20 trading sessions · Daily adjusted prices

GILD closed at $151.00 after 20 trading sessions, up 13.48% for the selected period.

Last close
$151.00
Period change
+13.48%
Period low
$133.06
Period high
$151.22
Daily close
View OHLC price history
GILD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 4, 2026$149.23$151.185$149.23$150.9956.18M
Sep 3, 2026$150.67$151.48$148.41$151.224.5M
Sep 2, 2026$150.00$152.55$148.83$149.614.92M
Sep 1, 2026$148.52$149.96$146.915$149.924.87M
Aug 31, 2026$144.23$147.22$143.175$146.346.59M
Aug 28, 2026$149.47$149.47$144.88$145.683.95M
Aug 27, 2026$147.30$149.105$146.01$148.865.01M
Aug 26, 2026$148.00$149.6199$147.004$148.095.26M
Aug 25, 2026$146.60$148.94$145.58$148.774.63M
Aug 24, 2026$145.93$146.835$144.59$146.746.18M
Aug 21, 2026$144.52$147.905$143.50$146.125.38M
Aug 20, 2026$146.69$146.82$143.19$143.447.17M
Aug 19, 2026$145.10$148.97$144.30$147.606.74M
Aug 18, 2026$140.00$143.89$139.54$143.445.76M
Aug 17, 2026$138.36$139.49$136.63$138.923.94M
Aug 14, 2026$136.81$138.4325$135.91$138.363.41M
Aug 13, 2026$136.94$138.30$136.03$138.144.9M
Aug 12, 2026$133.99$137.12$133.295$135.875.68M
Aug 11, 2026$132.68$136.85$132.01$135.775.49M
Aug 10, 2026$131.61$134.32$131.61$133.066.83M

Latest GILD news

The latest Smart Investors Daily articles mentioning GILD.

Stock researchCompany · Overview

GILD research

Overview

Company profile and research snapshot.

Company profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$130.64
Implied upside
—
Analysts
16
GILD recent ratings
DateFirmRatingTarget
Aug 5, 2026RBC CapitalSector Perform—
Aug 5, 2026Cantor FitzgeraldOverweight—
Aug 5, 2026NeedhamBuy—
Jul 29, 2026BarclaysEqual-Weight—
Jul 27, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?

Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...

Yahoo · Sep 4, 2026

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By